Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 224 Lymphoma, Large B-Cell, Diffuse 160 Small Cell Lung Carcinoma 154 Precursor Cell Lymphoblastic Leukemia-Lymphoma 143 Lymphoma, Non-Hodgkin 139 Leukemia 135 Leukemia, Myeloid, Acute 117 Hodgkin Disease 106 Lung Neoplasms 99 Burkitt Lymphoma 99 Lymphoma, Follicular 85 Lymphoma, Mantle-Cell 76 Lymphoma, Large-Cell, Immunoblastic 68 Carcinoma, Non-Small-Cell Lung 61 Neuroblastoma 60 Leukemia, Lymphocytic, Chronic, B-Cell 56 Recurrence 53 Multiple Myeloma 52 Lymphoma, B-Cell, Marginal Zone 43 Congenital Abnormalities 43 Sarcoma 39 Central Nervous System Neoplasms 39 Myelodysplastic Syndromes 35 Brain Neoplasms 34 Ovarian Neoplasms 32 Leukemia, Myelomonocytic, Acute 32 Lymphoma, B-Cell 31 Leukemia, Monocytic, Acute 31 Leukemia, Erythroblastic, Acute 31 Testicular Neoplasms 30

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Malignant Disease × Etoposide × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡